Sigachi Industries Boosts R&D With New Hyderabad Facility, Investing $1 Million

Sigachi Industries Limited (NSE: SIGACHI), one of the notable pharma companies, has brought to light the opening of a new state-of-the-art research and development (R & D) Center in Hyderabad that will help boost the industry's innovation and growth significantly and sustain it long term. This initiative is expected to centralize critical API development and analytics business functions with the initial investment of up to 1 million USD to be spent commencing immediately.

The new Center will improve API production by automating processes and complying with global high regulatory standards. The facility will ensure sustainable growth by broadening Sigachi's development pipeline, expediting the company's R&D activities, and optimizing the pharmaceutical product portfolio. The Center will have 15-20 highly profiled scientists specializing in R&D to work on targeted APIs and Intermediates, creating a consolidated approach for the specialized API production, as well as, regulatory submissions.

Sigachi is aiming to improve API development through innovation in the spirit of delivering better quality products and better lives globally. With the intention of achieving sustained profitability and market leadership, the company augments high-value innovation with the introduction of 6 new Certificates of Suitability (CEPs) within the next 6 months. These investments will enhance the magnitude of developing existing and new molecules, further solidifying Sigachi's direction for enduring profitability and market leadership.

Besides the steps taken towards advancement in R&D, Sigachi has successfully released Q3 FY25 and the nine-month results of FY25. During this quarter, the company's revenue increased by 26 per cent year on year resulting in Rs 139.42 crore. The company's EBITDA also rose, increasing by 45 percent to Rs 35.19 crore and consolidated net profit during Q3 FY25 was up 33 percent to Rs 21.35 crore. In the nine month period, revenue increased to Rs 360.03 crore which is 22 percent compared to the previous fiscal year. EBITDA climbed by 39 percent to Rs 89.75 crore and consolidated PAT grew by 33 percent to Rs 56.29 crore.

Similarly, it is evident that Sigachi's stock prices also performed well, climbing 1.74% from the previous Rs 44.71 to close at Rs 45.49 per share. Alongside this, the stock currently sits at 5% above its 52-week low of Rs 43.42 and the company is also currently valued at over Rs.1,500 crores. This demonstrates strong confidence from investors, due to the consistent profit growth of 25% CAGR over the last five years.

Sigachi Industries Limited is a prominent provider of high-quality excipients, vitamin-mineral nutrient blends, APIs and O&M services. They are listed on NSE and BSE and with over 35 years of experience in the industry, Sigachi is a trusted partner for pharmaceutical and nutraceutical companies globally. Sigachi specializes in food stability and fortification and offers blends designed to satisfy constantly changing consumer needs. They use advanced blending, encapsulation, and spray-drying technologies to empower food manufacturers to produce better-tasting, high quality and nutritious food. Sigachi contributes to a healthier world by striving to provide in-demand healthy food products.